Topics

Bayer/J&J eye new paediatric use for anticoagulant Xarelto

08:07 EDT 9 Jul 2019 | pharmaphorum

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagulant. The companies announced results of the phase 3 EINSTE...

Original Article: Bayer/J&J eye new paediatric use for anticoagulant Xarelto

NEXT ARTICLE

More From BioPortfolio on "Bayer/J&J eye new paediatric use for anticoagulant Xarelto"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...